David Risinger

“We think this novel mechanism, this amylin analog … will offer a major new treatment alternative for patients, both as a monotherapy and as a combination therapy. ”

David Risinger · said date not stated · reported 2026-10-02

Risinger told CNBC he expects eloralintide's amylin mechanism to offer a major new treatment alternative as both a monotherapy and a combination therapy.

“There are millions of individuals, potentially over 10 million people, who have tried GLP-1s and failed due to efficacy reasons, tolerability issues, or genetic issues where they simply do not respond to one,”

David Risinger · said date not stated · reported 2026-10-02

Risinger told CNBC that millions of people who have tried GLP-1s and failed represent a large potential patient pool for amylin-based treatments.